Combination Tablet with Chewable COX Inhibitor Layer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current formulations of niacin, particularly the immediate release form (niacin IR), cause significant flushing side effects and low patient compliance due to frequent dosing requirements, which are not adequately mitigated by existing sustained or extended release forms, and require concurrent administration of NSAIDs to manage these side effects.
Innovation Solution
A combination tablet design with a rapidly absorbed COX inhibitor layer and a slowly released niacin IR layer, where the COX inhibitor is absorbed through the buccal mucosa and niacin IR is absorbed through the gastrointestinal tract, coordinating their release to inhibit prostaglandin-mediated flushing and maintain therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If immediate release form of niacin is administered, then lipid-lowering efficacy is achieved, but flushing side effects occur and patient compliance decreases
Solution Approach 1:
The tablet is divided into two distinct layers: an inner layer containing niacin IR for lipid-lowering efficacy, and an outer chewable layer containing COX inhibitor for flushing mitigation. This segmentation allows each component to be optimized independently while working together to resolve the contradiction between efficacy and side effects.
Solution Approach 2:
The outer COX inhibitor layer is designed to be absorbed first through the buccal mucosa before the niacin IR is released from the inner layer. This preliminary action ensures that COX inhibition is established prior to niacin absorption, preventing prostaglandin-mediated flushing while maintaining lipid-lowering efficacy.
2Object-affected harmful factors
If sustained or extended release forms of niacin are used, then flushing side effects are reduced, but lipid-lowering efficacy is not adequately maintained
Solution Approach 1:
The invention merges the advantages of immediate release niacin (rapid lipid-lowering efficacy) with the advantages of COX inhibitors (flushing mitigation). By combining niacin IR with a COX inhibitor in a single tablet with coordinated release profiles, the invention achieves both rapid efficacy and side effect reduction that neither formulation alone can provide.
3Object-affected harmful factors
If COX inhibitor is administered with niacin IR, then flushing side effects are mitigated, but pharmacokinetic incompatibility arises due to different absorption rates
Solution Approach 1:
The tablet structure provides different local qualities for different layers: the outer layer is formulated for rapid buccal absorption of COX inhibitor, while the inner layer is formulated for gastrointestinal absorption of niacin IR. This local differentiation of absorption characteristics resolves the pharmacokinetic incompatibility by ensuring each component is absorbed through the most appropriate route at the optimal rate.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This design reduces flushing side effects and improves patient compliance by synchronizing the absorption of niacin and COX inhibitors, maintaining lipid-lowering efficacy while minimizing gastrointestinal intolerance and hepatotoxicity.
Implementation Method 1
the COX inhibitor is absorbed through the buccal mucosa
Implementation Method 2
niacin IR is absorbed through the gastrointestinal tract
Implementation Method 3
inhibit prostaglandin-mediated flushing
Data Source
AI summary
A pharmaceutical composition in the form of a combination tablet is described. The tablet has a rapidly absorbed component that enters the circulation by traversing the buccal mucosa, oral mucosa and combinations thereof, and a more slowly absorbed component that is swallowed. The therapeutic agent in the swallowed portion is absorbed across the gastric mucosa. The combination tablet may be modified, by varying the specific combinations of excipients, fillers, and the like to effect distinct release rates. In addition, the rapid and slow components may have identical or different therapeutic agents depending on the application to a specific medical condition. One embodiment of the combination tablet includes a prostaglandin inhibitor in the rapidly absorbed component in order to mitigate the side effects of immediate release niacin that is in the slow absorbing component. Such combination compositions will increase patient compliance with various dosing regimens due to the resultant decrease in the number of tablets that a patient would need to take on a daily basis.